Cannabidiol in Drug-Resistant Epilepsy and Beyond

Lakshminarayanan Kannan

doi:10.1055/s-0044-1801810

International Journal of Epilepsy, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · International Journal of Epilepsy 2025; 11(01): 002-003
DOI: 10.1055/s-0044-1801810

In the Spotlight

Cannabidiol in Drug-Resistant Epilepsy and Beyond

Lakshminarayanan Kannan

¹Advanced Centre for Epilepsy, Gleneagles Health City, Perumbakkam, Chennai, Tamil Nadu, India

References
1 Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28 (02) 153-157
2 Devinsky O, Cross JH, Laux L. et al. Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376 (21) 2011-2020
3 Miller I, Scheffer IE, Gunning B. et al. GWPCARE2 Study Group. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol 2020; 77 (05) 613-621
4 Devinsky O, Patel AD, Cross JH. et al. GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018; 378 (20) 1888-1897
5 Thiele E, Marsh E, Mazurkiewicz-Beldzinska M. et al. Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia 2019; 60 (03) 419-428
6 Silvinato A, Floriano I, Bernardo WM. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Rev Assoc Med Bras (1992) 2022; 68 (10) 1345-1357
7 Thiele EA, Bebin EM, Filloux F. et al. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: an open-label extension trial. Epilepsia 2022; 63 (02) 426-439
8 Lattanzi S, Brigo F, Trinka E. et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 2018; 78 (17) 1791-1804
9 O'Brien TJ, Berkovic SF, French JA. et al. STAR 1/STAR 2 Study Group. Adjunctive transdermal cannabidiol for adults with focal epilepsy: a randomized clinical trial. JAMA Netw Open 2022; 5 (07) e2220189
10 Chesney E, Oliver D, Green A. et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 2020; 45 (11) 1799-1806
11 Fazlollahi A, Zahmatyar M, ZareDini M. et al. Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis. JAMA Netw Open 2023; 6 (04) e239126